Interaction between paliperidone extended release and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient

Norio Yasui-Furukori, Kojiro Hashimoto, Kazutoshi Kubo, Tetsu Tomita Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan Abstract: Until now there has been no information available on drug interaction between paliperidone and TS-1®, an oral an...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yasui-Furukori N, Hashimoto K, Kubo K, Tomita T
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://doaj.org/article/ca6b542bbbdb401981d02d6907e26979
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:ca6b542bbbdb401981d02d6907e26979
record_format dspace
spelling oai:doaj.org-article:ca6b542bbbdb401981d02d6907e269792021-12-02T09:18:02ZInteraction between paliperidone extended release and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient1176-63281178-2021https://doaj.org/article/ca6b542bbbdb401981d02d6907e269792013-03-01T00:00:00Zhttp://www.dovepress.com/interaction-between-paliperidone-extended-release-and-ts-1reg-an-oral--a12352https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Norio Yasui-Furukori, Kojiro Hashimoto, Kazutoshi Kubo, Tetsu Tomita Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan Abstract: Until now there has been no information available on drug interaction between paliperidone and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative. The patient in the case presented here was a 39-year-old man with a 15-year history of schizophrenia. The patient's usual treatment of 2 mg/day of risperidone was changed to 3 mg/day of paliperidone extended release. He experienced worsening psychotic symptoms after switching from risperidone to paliperidone while he was also receiving TS-1. Retrospective analyses showed plasma concentration of paliperidone was consistently lower during the treatment with TS-1 than without TS-1. This case suggests there is drug interaction between paliperidone extended-release tablets and TS-1. Keywords: schizophrenia, antipsychotic, OROS, diarrhea, Positive and Negative Syndrome ScaleYasui-Furukori NHashimoto KKubo KTomita TDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 317-320 (2013)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Yasui-Furukori N
Hashimoto K
Kubo K
Tomita T
Interaction between paliperidone extended release and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient
description Norio Yasui-Furukori, Kojiro Hashimoto, Kazutoshi Kubo, Tetsu Tomita Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan Abstract: Until now there has been no information available on drug interaction between paliperidone and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative. The patient in the case presented here was a 39-year-old man with a 15-year history of schizophrenia. The patient's usual treatment of 2 mg/day of risperidone was changed to 3 mg/day of paliperidone extended release. He experienced worsening psychotic symptoms after switching from risperidone to paliperidone while he was also receiving TS-1. Retrospective analyses showed plasma concentration of paliperidone was consistently lower during the treatment with TS-1 than without TS-1. This case suggests there is drug interaction between paliperidone extended-release tablets and TS-1. Keywords: schizophrenia, antipsychotic, OROS, diarrhea, Positive and Negative Syndrome Scale
format article
author Yasui-Furukori N
Hashimoto K
Kubo K
Tomita T
author_facet Yasui-Furukori N
Hashimoto K
Kubo K
Tomita T
author_sort Yasui-Furukori N
title Interaction between paliperidone extended release and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient
title_short Interaction between paliperidone extended release and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient
title_full Interaction between paliperidone extended release and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient
title_fullStr Interaction between paliperidone extended release and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient
title_full_unstemmed Interaction between paliperidone extended release and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient
title_sort interaction between paliperidone extended release and ts-1®, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient
publisher Dove Medical Press
publishDate 2013
url https://doaj.org/article/ca6b542bbbdb401981d02d6907e26979
work_keys_str_mv AT yasuifurukorin interactionbetweenpaliperidoneextendedreleaseandts1ampreganoralanticancerdrugcontaininga5fluorouracilderivativeinaschizophrenicpatient
AT hashimotok interactionbetweenpaliperidoneextendedreleaseandts1ampreganoralanticancerdrugcontaininga5fluorouracilderivativeinaschizophrenicpatient
AT kubok interactionbetweenpaliperidoneextendedreleaseandts1ampreganoralanticancerdrugcontaininga5fluorouracilderivativeinaschizophrenicpatient
AT tomitat interactionbetweenpaliperidoneextendedreleaseandts1ampreganoralanticancerdrugcontaininga5fluorouracilderivativeinaschizophrenicpatient
_version_ 1718398212072538112